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Durability of carotid endarterectomy
Ecker RD, Pichelmann MA, Meissner I, Meyer FB. Stroke 2003;34:2941-4.
Conclusion: In a consecutive series of 1000 carotid endarterectomies
(CEAs), the authors had a 30-day all stroke and death rate of 1.9% and a
recurrent stenosis rate (70% stenosis) in the operated artery of 0.1%, with
a mean time to recurrence of 4  2 years.
Summary: This is a report of 1000 consecutive CEAs from the De-
partment of Neurosurgery at the Mayo Clinic. There were 680 men, 320
women, aged 69  8 years. Follow-up averaged 7.1 years (range, 2 to 11
years). Symptomatic internal carotid artery stenosis was present in 59% of the
patients. All CEAs were performed with preoperative aspirin, intraoperative
heparin, intraoperative EEG monitoring, and selective shunting based on
EEG changes. Routine patch closure was used.
The combined 30-day all stroke and death rate was 1.9%. There were
9 deaths (0.9%); 6 were neurologic and 3 were cardiac. There were 10
strokes (1.0%). Of the 10 strokes, 7 made good recovery. Recurrent
internal carotid artery stenosis of 70% as documented by duplex
scanning was found in only 10 patients (0.1%). The mean time to
recurrence was 4  2 years and only 2 of the recurrences were
symptomatic.
Comment: This is another of a number of large, single institutional
series of carotid endarterectomies documenting excellent short-term mor-
bidity and mortality and long-term durability of CEA. This, and similar
studies, have likely been stimulated by the increasing “visibility” of carotid
stenting. The results of this study, however, while excellent, will have
absolutely no impact on the debate of CEA versus carotid stenting. A
properly performed randomized trial is required.
Effects of Benzafibrate and Simvastatin on endothelial activation and
lipid peroxidation in hypercholesterolemia: Evidence of different vas-
cular protection by different lipid-lowering treatments
Desideri G, Groce G, Tucci M, et al. J Endocrinol Metab 2003;88:5341-7.
Conclusion: Circulating levels of endothelial adhesion molecules in
hypercholesterolemic patients are decreased with Simvastatin but not Ben-
zafibrate.
Summary: Endothelial adhesion molecule–mediated leukocyte adhe-
sion and transendothelial migration are fundamental steps in atherogen-
esis. The authors studied the effects in hypercholesterolemic patients of
two lipid-lowering agents on circulating levels of endothelial adhesion
molecules. Never-treated hypercholesterolemic outpatients (n 67) and
32 controls matched for sex, age, blood pressure, inflammatory indexes,
and acute phase reactive proteins were studied. Hypercholesterolemic
patients were divided into four groups. Group 1 was treated with
simvastatin (40mg/d), group 2 received benzafibrate (80mg/d), group
3 was treated with simvastatin plus vitamin E, and group 4 was treated
with benzafibrate plus vitamin E. Circulating levels of intercellular adhe-
sion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-
1), and E-selectin were evaluated at baseline in all four patient groups and
controls, and in the four patient groups following 1, 3, 4, and 6 months
of treatment.
Circulating ICAM-1, VCAM-1, and E-selectin levels were higher in the
hypercholesterolemic patient groups (groups 1-4) than in control subjects.
Both simvastatin (group 1) and benzafibrate (group 2), significantly reduced
total and low-density lipoprotein (LDL) cholesterol concentrations (P 
.0001). Simvastatin treatment was more effective than benzafibrate. Vitamin
E supplementation did not further reduce total or LDL cholesterol levels in
either simvastatin- or benzafibrate-treated patients.
Plasma ICAM-1, VCAM-1, and E-selectin significantly decreased dur-
ing the 6 months of the simvastatin treatment (P  .0001). There was no
decrease in endothelial adhesion molecule levels in patients treated with
benzafibrate alone. The addition of vitamin E resulted in further decreases in
endothelial adhesion molecules in patients treated with simvastatin and in a
decrease in endothelial adhesion molecules in the patients treated with
benzafibrate (P  .0003 to P  .0001).
Comment: The data demonstrate drug-induced cholesterol lowering
is not necessarily associated with a reduction of endothelial activation in
hypercholesterolemic patients. The beneficial effects of statin therapy in
treatment of patients with hypercholesterolemia may be independent of, or
additive to, cholesterol-lowering effects.
Measures of obesity are associated with vascular stiffness in young and
older adults
Wildman RP, MacKey RH, Bostom A, et al. Hypertension 2003;42:468-73.
Conclusion: Measures of excess body weight are associated with
increased levels of aortic stiffness in both African American and white
populations, in both older subjects and subjects as young as 20 to 30 years of
age.
Summary: Aortic pulse-wave velocity (aPWV) is a measure of aortic
stiffness. Arterial stiffening predisposes patients to hypertension and aging of
the vascular system. In this study, the association between aPWV and
measures of obesity was determined in 186 younger adults (20 to 40 years)
and 177 older adults (41 to 70 years). Measures of obesity evaluated
included body weight, body mass index (BMI), waist and hip circumfer-
ences, and waist-to-hip ratio.
Median aPWV was 627cm/s for older adults and 468cm/s for younger
adults (P  .001). Higher pulse-wave velocity correlated with higher levels
of all measures of obesity (p  0.01 for all measures). Twenty- to 30-year-
old obese individuals (BMI 30) had an aPWV 47cm/s higher than that of
nonobese individuals (P  .001). In all cases, obesity measurements were
strong independent predictors of aPWV. Results were consistent by race
even in individuals as young as 20 to 30 years of age.
Comment: The precise mechanism whereby excess weight adversely
affects the cardiovascular system is unknown. It is known, however, that
increased arterial stiffness predisposes to hypertension, which is a strong risk
factor for vascular disease. This study suggests one mechanism for an
increased risk of vascular disease in young obese patients as they age.
Endovascular stent graft repair of abdominal and thoracic aortic aneu-
rysms: A 10-year experience with 817 patients
Marin ML, Hollier LH, Ellozy SH, et al. Annals of Surgery 2003;238:586-
95.
Conclusion: A total of 817 patients were treated with abdominal aortic
(AA) or thoracic aortic (TA) stent grafts. Initial technical success was 93.8%,
perioperative mortality was 2.3%, primary clinical success was 65  6% at 8
years, and 5-year survival was 47  4%.
Summary: This is the experience of a single surgeon over 10 years who
placed endovascular stent grafts in 817 patients at two institutions. There
were 723 AA stent grafts and 94 TA stent grafts. Twelve different devices
were used. Mean patient age was 74.3 years. Based on an intent-to-treat
analysis, the overall technical success rate was 93.8% (94.9% for AA grafts and
85.1% for TA grafts). Type I or III endoleaks occurred in 7% of AA grafts and
15% of TA grafts. Type II endoleaks occurred in 21% of AA grafts and 10%
of TA grafts. Primary clinical success (freedom from aneurysm-related death,
graft infection, thrombosis, rupture, conversion to open repair, or develop-
ment of Type I or Type III endoleak) was 65 6% at 8 years. Device fatigue
occurred in 7.8%. Freedom from aneurysm rupture was 98  1% at 9 years.
Overall survival at 5 years was 47  4%.
Comment: The great discrepancy between clinical success rates (65 
6% at 8 years) and freedom from rupture (98 1% at 9 years) suggests
stent grafts for aortic aneurysmal disease are effective at preventing
aneurysm rupture but at a cost of many secondary procedures. This is a
10-year series. Undoubtedly, clinical success has improved in the more
recent patients. Given the author’s data, and the most recent FDA memo
on endovascular stent grafting for abdominal aortic aneurysms, the
concluding sentence of this report, “While significant advances have
occurred since the initial experiences, additional improvements are es-
sential before [endovascular stent grafting] becomes the standard of
care,” is appropriate.
The association of initial hemodialysis access type with mortality out-
comes in elderly Medicare ESRD patients
Zue JL, Dahl D, Eben JP, Collins AJ. Am J Kidney Dis 2003;42:1013-9.
Conclusion: The type of initial hemodialysis access is associated with
rates of one-year mortality in the US Medicare dialysis population. Mortality
risk is lowest with fistula, intermediate with grafts, and highest with venous
catheters.
Summary: Incident Medicare hemodialysis patients (N  66,595)
who were 67 years of age at time of dialysis initiation were studied with
respective CPT and ICD-9 codes to assess the effect of initial access type on
patient survival. A Cox regression analysis correcting for incidence year, sex,
age, diabetes, race, body mass index, initial access type, days from first access
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placement to initial dialysis date, and serum creatinine, albumin, and blood
urea nitrogen levels was used to assess the risk of death within one year of
initiation of hemodialysis.
Crude one-year death rates were 24.9%, 28.1%, and 41.5% for patients
with fistulae, synthetic grafts, and hemodialysis catheters, respectively. Pa-
tients with fistulae had the lowest likelihood of death compared with patients
with synthetic grafts (hazard ratio, 1.160; 95% confidence interval, 1.084-
1.241) or catheters (hazard ratio, 1.696; 95% confidence interval 1.593-
1.806); P  .0001.
Comment: The findings of this study support the Disease Outcomes
Quality Initiative (DOQI) guidelines for vascular access in dialysis patients.
DOQI encourages the use of native arteriovenous fistula for dialysis access
and suggests grafts and catheters be reserved for patients whose anatomy
does not permit fistula creation. Fistula placement, however, requires plan-
ning. Data in this study may reflect earlier referral to a nephrologist and
better general medical management in patients undergoing fistula place-
ment. In addition, patients with suitable arteries and veins for fistula con-
struction may be healthier overall than patients requiring a venous catheter
or a prosthetic graft.
Deep vein thrombosis and air travel: Record linkage study
Kelman CW, Kortt MA, Becker NG, et al. BMJ 2003;327:1072-5.
Conclusion: The annual risk of venous thromboembolism (VTE) is
increased by 12% with one long-haul flight a year. The highest risk is within
two weeks of the flight.
Summary: Hospital discharge summaries from 1981 to 1999 were
reviewed for all patients in western Australia admitted with the principle
diagnosis of VTE (deep venous thrombosis or pulmonary embolism).
Discharge summaries were matched with travel records of patients arriv-
ing on international flights to western Australia during the study period.
Statewide incidence information was used to estimate expected age- and
sex-specific incidences of VTE events.
During the study period, 4.8 million Australian citizens and 4.6
million non-Australian citizens arrived in western Australia on interna-
tional flights. During the same period, there were 16,205 hospital
admissions for VTE. There were 153 Australian citizens diagnosed
with VTE within 100 days of arrival on an international flight, with 46
VTE events occurring within 14 days of arrival and 107 events between
15 and 100 days of arrival. The number of VTE events within 14 days
statistically exceeded the number expected, assuming a uniform distribu-
tion over 0 to 100 days (P  .001; relative risk of 4.17; 95% confidence
interval, 2.94-5.40). VTE was attributed to the international flight in
76% of cases. Assuming one long-haul flight per year, additional risk from
this exposure amounts to a 12% increase in annual risk of VTE for
travelers.
Comment: The risk of air travel associated VTE is small, but likely
underestimated by this study. There may be a substantial “healthy
traveler” effect. Patients engaging in long-haul flights are likely to be
healthier overall than non–international traveling patients and therefore
at less risk of VTE. Comparing VTE rates in long-haul travelers to the
population as a whole may actually underestimate the risk in the long-
haul traveler.
Lp(a) lipoprotein, vascular disease, and mortality in the elderly
Raiyo AA, Thach C, Tracy R, and the Cardiovascular Health Study Investi-
gators. N Engl J Med 2003;349:2108-15.
Conclusion: An elevated level of Lp(a) in elderly patients is an inde-
pendent predictor of stroke, death from vascular disease, and all causes of
mortality in men but not women.
Summary: Men and women65 years of age, free of apparent vascular
disease and enrolled in the Cardiovascular Health Study, provided baseline
blood samples for analysis of Lp(a) lipoprotein. A total of 3972 subjects
(2375 women, 1597 men) were followed for a mean of 7.4 years. Subjects
were divided into quintile groups based on the level of Lp(a) at the time of
study entrance. End points included stroke, death from vascular disease, and
all-cause mortality.
Compared to men in the lowest quintile, men in the highest Lp(a)
quintile had three times the risk of stroke (relative risk [RR], 3.00; 95%
confidence interval [CI], 1.59-5.65), 2.5 times the risk of vascular death
(RR, 2.54; 95% CI, 1.9-4.08), and nearly a two times risk of all-cause
mortality (RR, 1.76; 95% CI, 1.0-2.36). Adjustment for multiple other
cardiovascular risk factors did not affect the final analysis. Analysis for women
revealed no relationship between Lp(a) lipoprotein levels and risk of stroke,
vascular death, or all-cause mortality.
Comment: Lp(a) lipoprotein is important in atherothrombogenesis.
This article is among the first to suggest that a serum risk factor for
atherogenesis may be sex-specific. Screening for Lp(a) levels in older males
should be considered.
Natural history of>60% asymptomatic carotid stenosis in patients with
contralateral occlusion
AbuRahma AF, Metz MJ, Robinson PA. Annals of Surgery 2003;238:551-
62.
Conclusion: Patients with a 60% to 70% internal carotid artery (ICA)
stenosis by duplex criteria and a contralateral ICA occlusion have a 27% five-year
stroke rate ipsilateral to the 60% to 70% ICA lesion, a 33% overall five-year stroke
rate, and a 28% incidence of progression to70% ICA stenosis.
Summary: The authors followed 82 patients with an ICA occlusion
and a 60% to 70% asymptomatic ICA stenosis in the remaining patent ICA.
Diagnosis of 60% to 70% ICA stenosis with a purported 95% positive
predictive value (PPV) was made by duplex criteria. Patients were treated
with antiplatelet therapy. Mean follow-up was 59.5 months (range, 7 to 141
months). There were 19 (23%) late strokes ipsilateral to the ICA stenosis and
8 (10%) late strokes on the side of the ICA occlusion. Transient ischemic
attacks occurred in 22 of the 82 patients (27%), 15 on the side of the ICA
occlusion and 7 on the side of the patent ICA. There was a 32% combined
transient ischemic attack/stroke rate ipsilateral to the patent ICA and a 28%
combined transient ischemic attack/stroke rate on the side of the ICA
occlusion. By Kaplan-Meier life table analysis, there was a 73% rate of
freedom from stroke ipsilateral to the ICA stenosis and an overall 67% rate of
freedom from all strokes at five years.
Comment: It makes sense that patients with an ICA occlusion and a
high-grade stenosis in the remaining ICA would have an adverse neurologic
prognosis. It is, however, questionable that the patients entered in this study
actually had a 95% PPV of a 60% to 70% stenosis in their only patent ICA.
Most experts on carotid ultrasound would disagree with a purported ability
to determine a 10% increment of ICA stenosis with a 95% PPV based on flow
values alone, especially in the presence of a contralateral ICA occlusion.
JOURNAL OF VASCULAR SURGERY
Volume 39, Number 4 Abstract 921
